Tetravanadate is an inhibitor of phosphatidyl inositol-specific phospholipase C

A. Stewart Campbell; Gregory R.J. Thatcher

doi:10.1016/S0960-894X(00)80384-4

Tetravanadate is an inhibitor of phosphatidyl inositol-specific phospholipase C

A. Stewart Campbell, Gregory R.J. Thatcher

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Monitoring of oligomer concentrations by ⁵¹V nmr demonstrates the tetramer of vanadate ion to be a potent inhibitor of phosphatidyl inositol specific phospholipase C (PI-PLC) from Bacillus Cereus.

Original language	English (US)
Pages (from-to)	655-658
Number of pages	4
Journal	Bioorganic and Medicinal Chemistry Letters
Volume	2
Issue number	7
DOIs	https://doi.org/10.1016/S0960-894X(00)80384-4
State	Published - Jul 1992
Externally published	Yes

ASJC Scopus subject areas

Biochemistry
Molecular Medicine
Molecular Biology
Pharmaceutical Science
Drug Discovery
Clinical Biochemistry
Organic Chemistry

Access to Document

10.1016/S0960-894X(00)80384-4

Cite this

@article{620e35a0c9a048979700754e67d76e06,

title = "Tetravanadate is an inhibitor of phosphatidyl inositol-specific phospholipase C",

abstract = "Monitoring of oligomer concentrations by 51V nmr demonstrates the tetramer of vanadate ion to be a potent inhibitor of phosphatidyl inositol specific phospholipase C (PI-PLC) from Bacillus Cereus.",

author = "{Stewart Campbell}, A. and Thatcher, {Gregory R.J.}",

note = "Funding Information: 1. For example:( a) Berridge,M .J. and Irvine, R.F., Nuture 1989&, & 197-205(:b ) Majerus, P.W., Ross, T.S., Cunningham,T .W., Caldwell, K.K., Jefferson, A.B., Bansal, V.S., Cell 1990,a , 459-465. 2. (a) Low, M.G. and Saltiel, A.R., Science 1988, m, 268-275; (b) Czech, M.P., Klarlund, J.K., Yagaloff, K.A., Bradford, A.P., Lewis, R.F., J. Biol. Chem. 1988, &$ 11017-11020. 3. Rhee, S.G., Suh, P.-G., Ryu, S.-H., Lee, S.Y., Science1 9892, 44,5 46-550. 4. (a) Wilson, D.B., Connolly, T.M., Bross, T.E., Majerus, P.W., Sherman,W .R., Tyler, A.N., Rubin, L.J., Brown, J.E., J. Biol. Chem. 1985, m, 13496-13501; (b) Connolly, T.M., Wilson, D.B., Bross,T .E., Majerus, P.W., J. Biol. Chem. 1986,2 61, 122-126(;c ) Sekar, M.C., Dixon, J.F., Hokin, L.E., J. Biol. Chem. 1987, Xj& 340-344. 5. (a) Ikezawa, H. and Taguchi, R., Math. Enzymol. 1981, a, 731-741; (b) Volwerk, J.J., Shashidhar,M.S., Kuppe, A., Griffith, O.H., Biorhem. 1990Z, , 8056-8062. 6. No conversionf rom cIP to I-l-P was observedu nder normal assayc onditions. Only when the PI-PLC concentrationw as increasedb y lOO-foldw as there observedh ydrolysiso f cIP, albeit at an extremelys low rate{\textquoteright}. This observationi s in completea ccordw ith ref. 8. 7. Campbell, A.S. and Thatcher,G .R.J., Tefruhed. Lett. 1991, 2207-2210. 8. Lin, G., Bennet, C.F., Tsai, M.-D., Biochem. 1990, a, 2747-2757. 9. First presenteda t the 74* Canadian Chemical Conferencea nd Exhibition 1991,A bstr. No. 106. 10. (a) Fohr, K.J., Wahl, Y., Engling, R., Kemmer, T.P., Gratzl, M., Cell Calcium 1991, U, 735-742; (b) Randazzo,P .A., Olshan, J.S., Bijivi, A.A., Jarett, L., Arch. Biochem. Biophys. 1992, 292, 258-265: (c) Heyliger C.E., Tahiliani A.G., McNeil J.H., Science, 1985, m, 1474-77. 11. Decavanadateis shown to be an IP, antagonista t the IP, receptor”{\textquoteleft}. Orthovanadates timulatesP I-PLC activitylob. Both vanadatea nd GIcP have been shown to elicit insulinomimetica ctivit44b,.{\textquoteleft} OTi he interaction of tetravanadatew ith PI-PLC reportedi n this paper may either potentiateo r counteract theseo ther biological effectso f vanadatei on and must be taken into account. 12. Gresser,M .J. and Tracey, A.S., J. Amer. Chem. Sot. 1986,m , 19351939. 13. (a) Wlodawer,A ., Miller, M., Sjolin, L., Proc. Naf. Acud. Sci. USA 1983, && 3628-3631; (b) Borah, B., Chen, C.-W., Egan, W., Miller, M., Wlodawer,A ., Cohen, J.J., Biochem. 1985, 2, 2058-2067; (c) Lindquist, R.N., Lynn, J.L.Jr., Lienhard, G.E., J. Amer. Chem.S ot. 1973,p 5, 8762-8768. 14. Tracey, A.S. and Gresser,M .J., Can. J. Chem. 1988, M, 2570-2574. 15. (a) Rehder, D., Angew. Chem. Int. Ed. En&. 1991,X l, 148-167(;b ) Pope, M.T., Heteropoly and Isopoly-oxometalates. Springer-Verlag,N ew York, 1983. 16. (a) Crans, D.C., Willging, E.M., Butler, S.R., J. Amer. Chem.S ot. 1990,_ l&$ 427-432;( b) Crans D.C. & SchelbeS .M., Biochem. 1990, B, 6698-6706; (c) Crans D.C. & Simone C.M., Biochem. 199l,jQ, 673441; (d) Wittenkeller L., Abraha A., RamasamyR ., de Freitas D.M., Theisen L.A., Crans D.C, J. Amer. Chem. Sot. 1991,? _u, 7872-81. 17. Tetravanadateh as been reporteda s an enzymei nhibitor competitivew ith substratea nd/or cofactor16, but not previouslyi n the case of phosphatasea nd phosphotransferaseen zymes. 18. Tracey, A.S., Gresser,M .J., Galeffi, B., Inorg. Chem. 1988,Z , 157-161. 19. Tracey, A.S. and Gresser,M .J., Inorg. Chem. 1988,z, 26952702. 20. Tracey, AS., Gresser,M .J., Liu, S., J. Amer. Chem. Sot. 1988,6 1115,8 69-5874. 21. The x-intercept( Fig.2) gives an approximatem aximalv alue for K, of 96uM: a figure comparablet o values of K, previouslyr eportedf or tetravanadate16. 22. Fuchs, J., Mahjour, S., Pickardt, J., Angew. Cem. int. Ed. Engl. 1976.15, 374-375; Day V.W., Klemperer W.G. & Yagasaki A., Chem.L ett. 1990,1 267-70. 23. The lack of rigorous parameterizationfo r cyclic phosphatea nd vanadatei n MM calculationsandthe structuralv ariation in tetravanadatec rystals tructuresm ust be recognized. 24. Jaswal, J.S. and Tracey, A.S., Can. J. Chem. 1991,@ , 1600-1607. 25. NSERC(Canada) and Queen{\textquoteright}s University ARC are thankedf or financial support",

year = "1992",

month = jul,

doi = "10.1016/S0960-894X(00)80384-4",

language = "English (US)",

volume = "2",

pages = "655--658",

journal = "Bioorganic and Medicinal Chemistry Letters",

issn = "0960-894X",

publisher = "Elsevier Limited",

number = "7",

}

TY - JOUR

T1 - Tetravanadate is an inhibitor of phosphatidyl inositol-specific phospholipase C

AU - Stewart Campbell, A.

AU - Thatcher, Gregory R.J.

N1 - Funding Information: 1. For example:( a) Berridge,M .J. and Irvine, R.F., Nuture 1989&, & 197-205(:b ) Majerus, P.W., Ross, T.S., Cunningham,T .W., Caldwell, K.K., Jefferson, A.B., Bansal, V.S., Cell 1990,a , 459-465. 2. (a) Low, M.G. and Saltiel, A.R., Science 1988, m, 268-275; (b) Czech, M.P., Klarlund, J.K., Yagaloff, K.A., Bradford, A.P., Lewis, R.F., J. Biol. Chem. 1988, &$ 11017-11020. 3. Rhee, S.G., Suh, P.-G., Ryu, S.-H., Lee, S.Y., Science1 9892, 44,5 46-550. 4. (a) Wilson, D.B., Connolly, T.M., Bross, T.E., Majerus, P.W., Sherman,W .R., Tyler, A.N., Rubin, L.J., Brown, J.E., J. Biol. Chem. 1985, m, 13496-13501; (b) Connolly, T.M., Wilson, D.B., Bross,T .E., Majerus, P.W., J. Biol. Chem. 1986,2 61, 122-126(;c ) Sekar, M.C., Dixon, J.F., Hokin, L.E., J. Biol. Chem. 1987, Xj& 340-344. 5. (a) Ikezawa, H. and Taguchi, R., Math. Enzymol. 1981, a, 731-741; (b) Volwerk, J.J., Shashidhar,M.S., Kuppe, A., Griffith, O.H., Biorhem. 1990Z, , 8056-8062. 6. No conversionf rom cIP to I-l-P was observedu nder normal assayc onditions. Only when the PI-PLC concentrationw as increasedb y lOO-foldw as there observedh ydrolysiso f cIP, albeit at an extremelys low rate’. This observationi s in completea ccordw ith ref. 8. 7. Campbell, A.S. and Thatcher,G .R.J., Tefruhed. Lett. 1991, 2207-2210. 8. Lin, G., Bennet, C.F., Tsai, M.-D., Biochem. 1990, a, 2747-2757. 9. First presenteda t the 74* Canadian Chemical Conferencea nd Exhibition 1991,A bstr. No. 106. 10. (a) Fohr, K.J., Wahl, Y., Engling, R., Kemmer, T.P., Gratzl, M., Cell Calcium 1991, U, 735-742; (b) Randazzo,P .A., Olshan, J.S., Bijivi, A.A., Jarett, L., Arch. Biochem. Biophys. 1992, 292, 258-265: (c) Heyliger C.E., Tahiliani A.G., McNeil J.H., Science, 1985, m, 1474-77. 11. Decavanadateis shown to be an IP, antagonista t the IP, receptor”‘. Orthovanadates timulatesP I-PLC activitylob. Both vanadatea nd GIcP have been shown to elicit insulinomimetica ctivit44b,.‘ OTi he interaction of tetravanadatew ith PI-PLC reportedi n this paper may either potentiateo r counteract theseo ther biological effectso f vanadatei on and must be taken into account. 12. Gresser,M .J. and Tracey, A.S., J. Amer. Chem. Sot. 1986,m , 19351939. 13. (a) Wlodawer,A ., Miller, M., Sjolin, L., Proc. Naf. Acud. Sci. USA 1983, && 3628-3631; (b) Borah, B., Chen, C.-W., Egan, W., Miller, M., Wlodawer,A ., Cohen, J.J., Biochem. 1985, 2, 2058-2067; (c) Lindquist, R.N., Lynn, J.L.Jr., Lienhard, G.E., J. Amer. Chem.S ot. 1973,p 5, 8762-8768. 14. Tracey, A.S. and Gresser,M .J., Can. J. Chem. 1988, M, 2570-2574. 15. (a) Rehder, D., Angew. Chem. Int. Ed. En&. 1991,X l, 148-167(;b ) Pope, M.T., Heteropoly and Isopoly-oxometalates. Springer-Verlag,N ew York, 1983. 16. (a) Crans, D.C., Willging, E.M., Butler, S.R., J. Amer. Chem.S ot. 1990,_ l&$ 427-432;( b) Crans D.C. & SchelbeS .M., Biochem. 1990, B, 6698-6706; (c) Crans D.C. & Simone C.M., Biochem. 199l,jQ, 673441; (d) Wittenkeller L., Abraha A., RamasamyR ., de Freitas D.M., Theisen L.A., Crans D.C, J. Amer. Chem. Sot. 1991,? _u, 7872-81. 17. Tetravanadateh as been reporteda s an enzymei nhibitor competitivew ith substratea nd/or cofactor16, but not previouslyi n the case of phosphatasea nd phosphotransferaseen zymes. 18. Tracey, A.S., Gresser,M .J., Galeffi, B., Inorg. Chem. 1988,Z , 157-161. 19. Tracey, A.S. and Gresser,M .J., Inorg. Chem. 1988,z, 26952702. 20. Tracey, AS., Gresser,M .J., Liu, S., J. Amer. Chem. Sot. 1988,6 1115,8 69-5874. 21. The x-intercept( Fig.2) gives an approximatem aximalv alue for K, of 96uM: a figure comparablet o values of K, previouslyr eportedf or tetravanadate16. 22. Fuchs, J., Mahjour, S., Pickardt, J., Angew. Cem. int. Ed. Engl. 1976.15, 374-375; Day V.W., Klemperer W.G. & Yagasaki A., Chem.L ett. 1990,1 267-70. 23. The lack of rigorous parameterizationfo r cyclic phosphatea nd vanadatei n MM calculationsandthe structuralv ariation in tetravanadatec rystals tructuresm ust be recognized. 24. Jaswal, J.S. and Tracey, A.S., Can. J. Chem. 1991,@ , 1600-1607. 25. NSERC(Canada) and Queen’s University ARC are thankedf or financial support

PY - 1992/7

Y1 - 1992/7

N2 - Monitoring of oligomer concentrations by 51V nmr demonstrates the tetramer of vanadate ion to be a potent inhibitor of phosphatidyl inositol specific phospholipase C (PI-PLC) from Bacillus Cereus.

AB - Monitoring of oligomer concentrations by 51V nmr demonstrates the tetramer of vanadate ion to be a potent inhibitor of phosphatidyl inositol specific phospholipase C (PI-PLC) from Bacillus Cereus.

UR - http://www.scopus.com/inward/record.url?scp=0026726118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026726118&partnerID=8YFLogxK

U2 - 10.1016/S0960-894X(00)80384-4

DO - 10.1016/S0960-894X(00)80384-4

M3 - Article

AN - SCOPUS:0026726118

SN - 0960-894X

VL - 2

SP - 655

EP - 658

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

IS - 7

ER -

Tetravanadate is an inhibitor of phosphatidyl inositol-specific phospholipase C

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this